ReviewEuropean heart journal2022
Electrical management of heart failure: from pathophysiology to treatment.
Review in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Modeling day-long ECG signals to predict heart failure risk with explainable AI.NPJ digital medicine · 2026Article
- Thyroid dysfunction and risk of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy: a multicenter cohort study.Frontiers in endocrinology · 2026Article
- Catheter ablation vs rate control in atrial fibrillation with left ventricular systolic dysfunction and fibrosis: the CAMERA-MRI II trial.European heart journal · 2025Article
- Tachycardia-Induced Cardiomyopathy in ccTGA: Successful Ablation of Incessant Atrial Tachycardia From Right Pulmonary Sinus Cusp.JACC. Case reports · 2025Article
- Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives.Biomedicines · 2025Review
- The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2025Article
- Evaluating the efficacy, safety, and predictors of failure following cardiac resynchronization therapy in a developing country: an ambispective, multi-center study.Cardiovascular diagnosis and therapy · 2025Article
- Recent Advances in Cardiac Resynchronization Therapy: Current Treatment and Future Direction.Journal of clinical medicine · 2025Review
- Microarray-based analysis reveals a novel role of the miRNA-613/SNAI2/CXCR4 axis in atrial fibrillation.PloS one · 2025Article
- Prevalence of frequent premature ventricular contractions and left-ventricular systolic dysfunction in patients receiving Holter monitoring.Journal of cardiovascular electrophysiology · 2025Article
- "Form follows function": the developmental morphology of the cardiac atria.Physiological research · 2024Review
- Atrioventricular node ablation for atrial fibrillation in the era of conduction system pacing.European heart journal · 2024Review
- Advancing 3D Engineered In Vitro Models for Heart Failure Research: Key Features and Considerations.Bioengineering (Basel, Switzerland) · 2024Review
- Aging diastole - root cause for atrial fibrillation and heart failure with preserved ejection fraction.The journal of cardiovascular aging · 2024Article
- Management of Ventricular Arrhythmias in Heart Failure: Can Less Be More?Current cardiology reports · 2024Review
- The SK4 channel allosteric blocker, BA6b9, reduces atrial fibrillation substrate in rats with reduced ejection fraction.PNAS nexus · 2024Article
- Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF).The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Article
- Antiarrhythmic Treatment in Heart Failure.Current heart failure reports · 2024Review
- Abnormal Conduction-Induced Cardiomyopathy: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2023Review
- Long-Term Outcomes of Tachycardia-Induced Cardiomyopathy Compared with Idiopathic Dilated Cardiomyopathy.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 5 countries.
Funding
Abstract
Electrical disturbances, such as atrial fibrillation (AF), dyssynchrony, tachycardia, and premature ventricular contractions (PVCs), are present in most patients with heart failure (HF). While these disturbances may be the consequence of HF, increasing evidence suggests that they may also cause or aggravate HF. Animal studies show that longer-lasting left bundle branch block, tachycardia, AF, and PVCs lead to functional derangements at the organ, cellular, and molecular level. Conversely, electrical treatment may reverse or mitigate HF. Clinical studies have shown the superiority of atrial and pulmonary vein ablation for rhythm control and AV nodal ablation for rate control in AF patients when compared with medical treatment. Ablation of PVCs can also improve left ventricular function. Cardiac resynchronization therapy (CRT) is an established adjunct therapy currently undergoing several interesting innovations. The current guideline recommendations reflect the safety and efficacy of these ablation therapies and CRT, but currently, these therapies are heavily underutilized. This review focuses on the electrical treatment of HF with reduced ejection fraction (HFrEF). We believe that the team of specialists treating an HF patient should incorporate an electrophysiologist in order to achieve a more widespread use of electrical therapies in the management of HFrEF and should also include individual conditions of the patient, such as body size and gender in therapy fine-tuning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.